Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PENNEX CLASS III RECALL OF 50 MIL. OTC ANALGESIC, ALLERGY

Executive Summary

PENNEX CLASS III RECALL OF 50 MIL. OTC ANALGESIC, ALLERGY and vitamin tabs is expected to be completed by Aug. 1. The Verona, Pennsylvania company told its customers in a June 26 letter that a credit would be issued for all of the recalled merchandise returned or destroyed. Pennex manufactured the aspirin mainly for private label distribution by a broad range of customers including chain drug stores, supermarkets, independent pharmacy coops, and distributors. The aspirin products were recalled due to trace contamination with aromatic hydrocarbons discovered by the firm as a result of a handful of complaints regarding malodor in bottles. The company explained to its customers that the contamination was introduced by the solvent used in the coating procedure. The solvent, Pennex said, was originally made by Dow Chemical and shipped in bulk to Pittsburgh where it was put into a drum by a local company for Pennex use. Trace levels of the contaminant were apparently introduced into the solvent during shipping, Pennex said, and were not detected by the firm's normal testing procedures which included an assay of the solvent by the USP method. The company explained that "two months later, after many batches of tablets were made using this lot of solvent" the odor was discovered on the finished products, and the decision was made to issue the recall in spite of the fact that no health hazard was involved. Pennex told its customers that in addition to its normal testing procedures, it was instituting "odor tests" on all solvents and all finished tablets.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS010486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel